These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 16469459

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Preparation and characterization of freeze-dried 2-methoxyestradiol nanoparticle powders.
    Du B, Li XT, Zhao Y, A YM, Zhang ZZ.
    Pharmazie; 2010 Jul; 65(7):471-6. PubMed ID: 20662313
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour.
    Lai F, Sinico C, Ennas G, Marongiu F, Marongiu G, Fadda AM.
    Int J Pharm; 2009 May 21; 373(1-2):124-32. PubMed ID: 19429297
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Solution calorimetry as an alternative approach for dissolution testing of nanosuspensions.
    Kayaert P, Li B, Jimidar I, Rombaut P, Ahssini F, Van den Mooter G.
    Eur J Pharm Biopharm; 2010 Nov 21; 76(3):507-13. PubMed ID: 20887787
    [Abstract] [Full Text] [Related]

  • 8. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling.
    Liu P, Rong X, Laru J, van Veen B, Kiesvaara J, Hirvonen J, Laaksonen T, Peltonen L.
    Int J Pharm; 2011 Jun 15; 411(1-2):215-22. PubMed ID: 21458552
    [Abstract] [Full Text] [Related]

  • 9. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.
    Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM.
    Int J Pharm; 2007 Aug 01; 340(1-2):126-33. PubMed ID: 17600645
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine.
    Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K.
    Int J Pharm; 2005 Aug 11; 299(1-2):167-77. PubMed ID: 15996838
    [Abstract] [Full Text] [Related]

  • 12. Comminution of ibuprofen to produce nano-particles for rapid dissolution.
    Plakkot S, de Matas M, York P, Saunders M, Sulaiman B.
    Int J Pharm; 2011 Aug 30; 415(1-2):307-14. PubMed ID: 21683776
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Influence of microencapsulation method and peptide loading on formulation of poly(lactide-co-glycolide) insulin nanoparticles.
    Kumar PS, Ramakrishna S, Saini TR, Diwan PV.
    Pharmazie; 2006 Jul 30; 61(7):613-7. PubMed ID: 16889069
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.
    Mou D, Chen H, Wan J, Xu H, Yang X.
    Int J Pharm; 2011 Jul 15; 413(1-2):237-44. PubMed ID: 21540090
    [Abstract] [Full Text] [Related]

  • 20. Preparation of a chemically stable quercetin formulation using nanosuspension technology.
    Gao L, Liu G, Wang X, Liu F, Xu Y, Ma J.
    Int J Pharm; 2011 Feb 14; 404(1-2):231-7. PubMed ID: 21093559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.